Payment overview · 2025
General Payments
$1,207.60
34 reported records · 19 companies
Healthcare provider profile · identity verified
Brett A Butler, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · NORTH CANTON, OH · NPI 1366646325
Verified facts
What the public records show
CMS Open Payments records show Brett A Butler, MD received $1,207.60 in general payments during 2025 across 34 reported records.
Endologix LLC accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $165.52 | 13.7% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $153.35 | 12.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$146.08 | 12.1% | 6 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $137.69 | 11.4% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $137.29 | 11.4% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $81.81 | 6.8% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $68.88 | 5.7% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $46.38 | 3.8% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $45.18 | 3.7% | 2 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $37.12 | 3.1% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $36.00 | 3.0% | 1 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $33.24 | 2.8% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $23.63 | 2.0% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $19.91 | 1.6% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $19.29 | 1.6% | 1 | 2025 |
| Terumo Cardiovascular Systems Corporation | Unresolved — no canonical attribution shown | $15.99 | 1.3% | 1 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $15.21 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.20 | 1.2% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $10.83 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,207.60 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $165.52 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $165.52 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $153.35 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $137.69 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $84.58 | 3 | 2025 |
Source payment records
|
|||||
| FLOSEAL Normalized: floseal |
Biological | Baxter Healthcare | $68.88 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $67.82 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $52.71 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $46.38 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $45.18 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $45.18 | 2 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $33.24 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| ARROW Normalized: arrow |
Device | Teleflex LLC | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| TERUMO ADVANCED PERFUSION SYSTEM 1 Normalized: terumo advanced perfusion system 1 |
Device | Terumo Cardiovascular Systems Corporation | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| VIRTUOSAPH PLUS WITH RADIAL INDICATION Normalized: virtuosaph plus with radial indication |
Device | Terumo Cardiovascular Systems Corporation | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| General - Thrombectomy Normalized: general thrombectomy |
Device | Boston Scientific Corporation | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $10.83 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $10.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 549 | 140 |
| Cilostazol | Cilostazol | 163 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 78 |
| Eliquis | Apixaban | 68 | 14 |
| Prednisone | Prednisone | 30 | 23 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,207.60 · 34 records | Endologix LLC | ABRE, ARROW, ARTIX MT, CAMZYOS, CLOT MANAGEMENT, ENDOCROSS Device, ENDURANT IIS, ENROUTE Transcarotid Stent, ETHICON, EVARREST, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOSEAL, FLOWTRIEVER, Flexitouch Plus, General - Thrombectomy, HELI-FX ENDOANCHOR SYSTEM, HEMOBLAST BELLOWS, Nimbl, Pounce Thrombectomy, Pounce Venous Thrombectomy System, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Symvess, TERUMO ADVANCED PERFUSION SYSTEM 1, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VENASEAL, VIRTUOSAPH PLUS WITH RADIAL INDICATION, VISTASEAL, Varithena Administration Pack | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error